NCT01707082 - A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Healthy

Interventions

DRUG

PF-06282999

Tablet, 10 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 30 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 100 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 250 mg, every 8 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 hours, 14 days

DRUG

PF-06282999

Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days

DRUG

Placebo

Tablet, 0 mg, every 8 or 12 hours, 14 days

DRUG

midazolam

Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

DRUG

PF-06282999

Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days

DRUG

midazolam

Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

DRUG

PF-06282999

Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels